cannabidiol (CBD) / Claritas Pharma 
Welcome,         Profile    Billing    Logout  
 0 Diseases   2 Trials   2 Trials   40 News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cannabidiol (CBD) / Claritas Pharma
NCT03840512: An Open Label Study of Multiple Doses of Cannabidiol in the Prevention of Acute Graft-Versus-Host Disease (GVHD)

Active, not recruiting
2a
36
RoW
CBD
Kalytera Therapeutics Israel, Ltd.
Prevention aGVHD
11/22
12/22
ACTRN12619000623190: An open label, study to evaluate the safety of Cannabidiol (CBD) for the prevention of Acute Graft-Versus-Host Disease (GVHD) after allogeneic hematopoietic cell transplantation.

Recruiting
2
36
 
Kalytera Therapeutics Israel Ltd, Kalytera Therapeutics Israel Ltd.
Acute Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation
 
 

Download Options